Femasys Inc. (NASDAQ:FEMY) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Femasys Inc. (NASDAQ:FEMY) have been given a consensus recommendation of “Moderate Buy” by the five ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $5.50.

Several equities analysts recently issued reports on FEMY shares. Lake Street Capital started coverage on Femasys in a research report on Tuesday. They set a “buy” rating and a $1.50 price target on the stock. Wall Street Zen downgraded Femasys from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Femasys in a research report on Thursday, January 22nd. Finally, Laidlaw began coverage on shares of Femasys in a report on Thursday, November 20th. They issued a “buy” rating and a $6.50 target price on the stock.

Femasys Price Performance

Shares of NASDAQ FEMY traded down $0.01 during mid-day trading on Tuesday, reaching $0.53. 793,517 shares of the company were exchanged, compared to its average volume of 804,197. The company has a quick ratio of 0.61, a current ratio of 1.16 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $30.70 million, a PE ratio of -0.73 and a beta of -2.53. The company’s 50 day moving average price is $0.58 and its 200 day moving average price is $0.62. Femasys has a 52 week low of $0.31 and a 52 week high of $1.76.

Institutional Trading of Femasys

Institutional investors and hedge funds have recently modified their holdings of the company. Kovack Advisors Inc. bought a new stake in Femasys in the 4th quarter worth approximately $27,000. HRT Financial LP bought a new stake in Femasys in the fourth quarter worth $30,000. Cetera Investment Advisers purchased a new stake in Femasys during the fourth quarter valued at $36,000. Osaic Holdings Inc. bought a new position in Femasys during the second quarter valued at $45,000. Finally, State Street Corp lifted its position in Femasys by 43.5% during the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock valued at $47,000 after purchasing an additional 24,500 shares during the last quarter. 65.27% of the stock is currently owned by institutional investors.

About Femasys

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.